Dai­ichi Sankyo scraps ear­ly-stage ADC pro­gram in gas­troin­testi­nal tu­mors af­ter first phase fail

Dri­ven by a se­ries of wins for its an­ti­body-drug con­ju­gate pipeline, Dai­ichi Sankyo has earned a rep­u­ta­tion as an ADC ex­pert with a suc­cess­ful part­ner­ship …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER